Key result
Higher serum albumin linked to ~63% lower MACE risk only when total cholesterol is <200 mg/dL.
Why the study?
Most previous studies on albumin levels and CAD prognosis have not considered the effect of cholesterol levels on outcomes.
Does serum albumin level predict MACE in patients with stable CAD undergoing PCI, and is this modified by total cholesterol?
Cohort (n=204)
No
Does serum albumin level predict MACE in patients with stable CAD undergoing PCI, and is this modified by total cholesterol?
Hazard Ratio: 0.37 (95% CI 0.14–0.98)
p-value: p=0.0462
No takes yet. Share an insight, caveat, or question.
May mark lower MACE risk only in low-cholesterol patients; leaves open causal role and clinical utility.
Yao et al. (2022) conducted a cohort in Stable coronary artery disease (n=204). Serum albumin vs. Lower serum albumin was evaluated on Major adverse cardiac events (MACE) (HR 0.37, 95% CI 0.14-0.98, p=0.0462). Higher serum albumin levels were associated with a lower risk of major adverse cardiac events (HR 0.37), though this protective association was only significant in patients with total cholesterol < 200 mg/dL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: